The MNP 2.0 Study investigated the principle of using DNA methylation signatures as part of a combined histological and molecular tumor classification to improve diagnostic accuracy in pediatric neurooncology. Within this study, molecular diagnostics (including DNA methylation profiling complemented by targeted gene panel sequencing) were introduced into neuropathological diagnostics at the time of primary diagnosis, aiming to integrate reference neuropathological diagnosis, radiological evaluation, and molecular findings into one, multi-layered CNS tumor diagnosis.
Thereby the MNP 2.0 study paved the way for the comprehensive implementation of advanced molecular diagnostics into routine neuropathological assessment of primary CNS tumors in children and adolescents. All molecular analyses were performed in close collaboration with the Clinical Cooperation Unit Neuropathology.
After a run-time of 5 years and successful registration of more than 1,800 patients, recruitment for the MNP2.0 study is ending November 2020.
The MNP 2.0 was funded by the German Childhood Cancer Foundation and performed in cooperation with the HIT network of the Society for Pediatric Oncology and Hematology (GPOH).
